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Abstract: One possible response to the growing problem of Antimicrobial Resistance (AMR) in 
pathogenic infections is the development of new types of antibiotics. However, the 
pharmaceutical companies that have traditionally led such innovation face a lack of incentives 
at the present time due to high levels of market uncertainty and low expected returns. Mission 
oriented innovation with coordinated investment and market-shaping policies may offer an 
approach to accelerating antibiotic innovation. This paper aims to evaluate whether pre-
Covid-19 Chinese policies concerning AMR can be seen as constituting a mission-oriented 
approach and whether these policies have influenced antibiotics innovation in China. It adopts 
a mixed method approach to deliver several insights. By using historical event analysis based 
on data collected from interviews, public and commercial databases as well as policy 
documents, the paper finds that China’s recent actions concerning AMR since 2008 comprise 
many elements of mission-oriented innovation policy. The National Action Plan to Contain 
AMR has provided a clear mission since 2016 to tackle the problem of AMR and provides the 
opportunity to coordinate and integrate these policies into a more coherent and evolving 
mission-oriented innovation approach. Analysis of relevant research grants and publications 
suggest that these policies (including the 2016 National Action Plan) have drawn the scientific 
community towards antibiotics research and provided more support to this area. Case studies 
following the development of new antibiotics are used to illustrate how the established 
elements of mission oriented innovation policy have or have not contributed to antibiotics 
innovation in China. Further research is required to more comprehensively analyse R&D 
investments, and to understand the effects of recent policies, especially after 2016. 
 
Key Words: Antimicrobial Resistance, mission-oriented innovation, National S&T major 
research project, market shaping policy. 
1. Introduction 
Against the background of widespread and increasing rates of antimicrobial resistance (AMR) 
in pathogenic infections, exacerbated by the widespread use of antimicrobials during the 
Covid-19 pandemic, innovation to deliver new antibiotic medicines is becoming an important 
issue of global concern. Pharmaceutical companies characterize antibiotic drug R&D as having 
relatively low financial returns, with the result that few companies are willing to invest in this 
area, with antibiotic drug development pipelines becoming relatively depleted as a result. 
Between 2000 to 2016, only 5 novel classes of antibiotics were brought to market globally, 
significantly less than in the 1980s or 1990s, and none of these were targeted at the deadly 
and most readily drug resistant gram-negative bacteria (Renwick et al. 2016).  
The barriers to antibiotic innovation are diverse. The high risk of product failure and 
knowledge spill-overs during basic research prevents companies from investing in research in 
this phase and constrains the discovery of effective lead compounds (Mossialos et al. 2010). 
The expensive cost and uncertainty of preclinical testing hinders the role of academia and 
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entrepreneurs respectively, especially against a background of weak connectedness between 
them (Mossialos et al. 2010). The enormous cost of clinical trials reduces the efforts of SMEs 
which have been looked to as the primary investors in antibiotics (Renwick, Simpkin, and 
Mossialos 2016). The differences among the approval processes of different countries 
increase the cost for approving a new antibiotic in the absence of harmonized approaches 
(Van Zwanenberg et al. 2011). Furthermore, as they represent a rivalrous and non-renewable 
common pool resource (Foster and Grundmann 2006; Tarrant et al 2019), markets for 
antimicrobials are more uncertain (both temporally and in aggregate) because a) spread of 
resistance may curtail their utility and b) regulations to limit use may constrain adoption by 
the market.  Finally, the limited use, intense market competition and low profit margins for 
new antibiotics also represent adverse conditions for innovation (Chorzelski et al. 2015).  
The above barriers not only reflect the market failures inhibiting antibiotic innovation, but also 
systems failure and even directionality failures (Weber and Rohracher 2012; Schot and 
Steinmueller 2018). In response to these failures within the innovation system for new 
antibiotics, “mission-oriented” (Foray, Mowery, and Nelson 2012; Mazzucato et al. 2018; 
Mazzucato 2018a) approaches are alluring, with an emphasis on public investment in basic 
research at first coupled with  then a “market-entry reward” at later stages (O'Neill 2018).  
China is estimated to be the world’s largest consumer of antibiotics (Zhang et al. 2015).  
Excessive and irrational use of antibiotics leads to the development of AMR, which brings 
serious threats to Chinese health (Ying et al. 2017). Chinese and UK scholars have highlighted 
this in the past (Chen and Ely 2011) and over the past decade since 2008, China has gradually 
paid more attention to this issue and taken action to govern the use of antibiotics (Wang et al. 
2016). This paper investigates the additional response of developing new drugs against AMR, 
which is being viewed with greater importance by the international health community, and 
focuses on antibiotic innovation in China prior to the arrival of the Covid-19 pandemic.  
The innovation system of China has been changing rapidly in recent decades, especially since 
the reform and opening-up of the 1970s and 1980s (Oldham et al. 1997). Markets and 
competition have become increasingly valued characteristics of the Chinese innovation 
system. As a result, antibiotic innovation in China faces similar problems to those in Western 
markets. In drug development and other strategic areas, the objectives of ‘indigenous 
innovation’ and ‘technological independence’ have been important elements in subsequent 
Five Year Plans. The country’s innovation system has generated some successes in drug 
development, such as the anti-malarial drug artemisinin, which has its origins in traditional 
Chinese medicine and was developed in the 1970s1 (Guo 2016).  
China’s contemporary innovation system is regarded as a “whole nation system,” which 
emphasizes the government’s role in mobilizing resources nationwide to achieve pivotal goals 
and thus steering innovation and development. This notion originated from the description of 
China’s state-run sports system which used the resources to train athletes with high potential 
to win gold medals at the 2008 Beijing Olympics (Cao 2015). It was subsequently this applied 
to the understanding of China’ innovation system (Zhong 2009), and became an official term 
in Chinese Government policy (CPC/SC 2012).  The apparent similarity between the concept 
of “whole nation system” and a coordinated national system for “mission-oriented” (discussed 
later) innovation raises questions about the potential of China’s innovation in new antibiotics: 
does China have the institutions and policies in place to play a significant role in the global 
 
1 YouYou Tu won the 2015 Nobel prize in physiology and medicine for the discovery of the compound. 
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battle against AMR? 
In considering the above situation, this paper addresses the following questions:  
1. Do China’s policies to support antibiotics innovation have the characteristics of mission 
oriented innovation policy? If so, how was this policy framework established?  
2. How effective is antibiotic innovation in China? 
Section 2 introduces mission oriented innovation policy as a way of coordinating innovation 
within the context of a national system of innovation, in response to grand challenges. Section 
3 describes the mixed methods approach used in this research and data sources used. Section 
4 provides a summary of recent history in relation to China’s antibiotic innovation, whilst 
Section 5 describes funding and scientific output (publications). Section 6 describes the origins 
of China’s indigenous innovative antibiotics through a series of case studies. Section 7 provides 
a discussion of the empirical results and addresses the research questions above, and Section 
8 draws conclusions, including identifying the limitations of the study and providing 
suggestions for further research. 
 
2. Mission Oriented Innovation Policy: Historical and Contemporary Relevance  
It has been widely acknowledged that innovation does not only have speed but also direction 
(Rosenberg 1969; Freeman 1979), raising questions not of “how much?”/ “how fast?” but of 
“which way?”/ “who says?” and “why?” (Stirling 2009; Ely et al. 2013). Faced with “social 
challenges” or “grand challenges” (covering areas including health, clean energies, climate 
change and so forth - see Hicks 2016; Kuhlmann and Rip 2014), mission-oriented innovation 
is regarded as a possible response to the questions of direction (Mazzucato 2018b). Mission-
oriented innovation is to some extent inspired by the success of the iconic U.S. government-
sponsored Manhattan (atomic bomb) or Apollo (moon landing) projects (Foray, Mowery, and 
Nelson 2012). By integrating diverse resources and people under the guidance of specific goals, 
these projects achieved remarkable technological feats making them early models of mission-
oriented innovation. Yet, the original form of mission-oriented innovation could be said to 
date back to the late 19th century when “catching up” was the dominant idea for 
developmental states such as Germany (Kattel and Mazzucato 2018). Thereafter, innovation 
oriented towards defence and space exploration during the time of World War II and the Cold 
War progressed in a context in which the market was almost completely dominated by 
government actors (Mowery 2012).    
The newest incarnation of mission-oriented innovation has surpassed the earlier forms both 
in breadth of mission and complexity of policies, as it is assumed to tackle “grand challenges” 
(Foray, Mowery, and Nelson 2012). Such contemporary missions are totally different from 
earlier ones, being multi-dimensional, systemic in nature and involving a range of government 
and non-governmental actors. This represents one of the key characteristics of present day 
mission-oriented policies, such as innovation in the energy sector which not only targets 
energy security but also needs to consider climate change and economic competitiveness 
(Anadón 2012). Rapid and wide application of technology is seen as part of the solution to 
tackle such complex social challenges, with the implication that mission-oriented innovation 
should play an important role in affecting the demand for technologies, their direct use by 
government, public procurement and regulatory approaches (Foray, Mowery, and Nelson 
2012). From the supply side, public investment in basic R&D and in the dissemination of new 
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technologies is regarded as the most important form of support, but public policy should also 
catalyze or augment private sector investment.  
Mazzucato further developed the framework of mission-oriented innovation policy with 
sophisticated work on the distribution of public/private risks and rewards and a deeper 
consideration of the demand side to advocate the formation and shaping of new markets 
(Mazzucato 2016; Mazzucato 2018a; Kattel and Mazzucato 2018). Going beyond policies 
justified by “market fixing” (i.e. public investment in basic R&D, replacing the private R&D 
investment that is absent due to market failure), which Mazzucato argued do not provide the 
directionality demanded, mission-oriented innovation instead aims to create and shape new 
markets (Mazzucato 2016). The archetypical example of a mission oriented innovation policy 
organization – NASA - started its work by bringing different talents together to work on 
cutting-edge science and technology, in turn crowding in business and creating new 
expectations for the market. Finally, this results in a new, “co-shaped” market for space 
technologies (Mazzucato 2018b).  
In contrast to the older challenges (e.g. moon landing) new challenges are less circumscribed/ 
more systemic in nature, and much more relevant to social needs. As such, they should be co-
defined by various stakeholders (Mazzucato 2018b). The implementation of the mission 
oriented policy response must involve different sectors and a wide range of actors, in order to 
drive a systemic change. The process for designing and implementing mission-oriented 
innovation is necessarily complex but can be seen as incorporating various elements. 
First, a well-defined mission agreed by different stakeholders is needed to provide a vision and 
direction. Such a mission should be widely broadcast and should legitimize follow-up actions 
by various actors. Second, a portfolio/mix of policy tools are needed - grants, prizes, new 
forms of procurement and other financial instruments can be included in such a portfolio 
(Mazzucato 2018a). Third, all the policies across different sectors should be well-coordinated 
to overcome the coordination failures that have existed in other policy areas (Kattel and 
Mazzucato 2018). 
In this paper, we will take coordinated public research investments and market-shaping 
policies to stimulate the government, private and third sector experimentation and innovation 
as the two key elements of mission-oriented innovation. These two basic pillars (coordinated 




This paper adopts a mixed-method approach. In order to answer the questions outlined in 
section 1, we rely on numerous sources:  
• documentary evidence including policy texts relevant to antibiotics from government 
websites,  
• bibliometric data about publications on antibiotics from both Chinese language and 
English language publication databases,  
• quantitative data on investments in R&D from government reports and databases and  




The first question (Do China’s policies to support antibiotics innovation have the 
characteristics of mission oriented innovation policy? If so, how was this policy framework 
established?) is addressed using historical event analysis (Hekkert et al. 2007), drawing on 
relevant policy texts and analyzing policy changes to develop chronological descriptions and 
timelines (see Appendix 1). Where possible, we also trace public R&D expenditure using data 
on grants from the National Science Foundation of China (NSFC) from 2010 to 2019 to analyze 
the changes in public investment. These data are from https://www.letpub.com.cn/ (LetPub 
2019), a database exhibiting the NSFC grants over the past 10 years. We use “抗生素” 
(“antibiotics”) as the search string in this data base to identify the NSFC grants on antibiotics, 
as the search string “抗生素耐药性” (“antimicrobial resistance”) only returns very few grants, 
providing little information for further analysis.  Data from several other funding sources are 
unfortunately not available for the detailed analysis (see Table 1).  Documentary evidence to 
inform the historical event analysis and quantitative data on R&D spend are supplemented by 
evidence from elite interviews with scientists and policy researchers, as well as 
representatives of the China Food and Drugs Administration (CFDA), Ministry of Industry and 
Information Technology (MIIT), Ministry of Science and Technology (MOST), National Science 
Foundation of China (NFSC) and National Health Commission (NHC) (interviewees and major 
talking points are listed in the Appendix 2, although the names and key information about 
their position are omitted).  
 
Table 1 Major R&D Funding Sources in China and data availability 





The National High Technology R&D Program of China (863 
Program) 
1986-2016 yes 
The National Basic Research Program (973 Program) 1997-2016 yes 
National Key Technologies R & D Program 2006-2016 no 
International Science & Technology Cooperation Program of 
China 
2001-2016 no 
Special Fund for Research in the Public Interest (of different 
ministries) 
2006-2016 no 
Industrial Technology Research and Development Funds (of 
different ministries) 
?-2016 no 
National key R & D plan (integrating the above 6 program) 2016-present no 
National S&T Major Research Project 2001-present not detailed 
Natural Science Foundation of China 1986-present yes 
 
The second question (how effective is antibiotic innovation in China?) is addressed using 
English and Mandarin Chinese language searches indatabases to support bibliometric analysis 
in an attempt to understand the patterns of publication in different fields associated with AMR. 
Where possible, these data will be disaggregated by funding source in order to understand 
trends in the investment of major R&D funders. Chinese language bibliometric databases are 
used because many indigenous innovation-related research is not reflected in English 
language databases.  These Chinese language databases are often neglected in international 
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analyses due to the language barriers, diverse publication formats and even the lack of 
digitalization (Wagner and Wong 2011). Research articles published in Chinese will be 
analyzed based on CNKI, the largest database for Chinese journals. We use “抗生素耐药性 
(antimicrobial resistance)” as the subject term search string to search in CNKI within the 
research area of pharmacy, as there are other research areas which also relate to AMR (such 
as environment, economy and biology). The time period used runs from 1989 to 2019 (until 
December of 2019). 
The analysis of English publications is based on PubMed and Web of Science. Within PubMed, 
searching by using MESH (Medical Subject Headings) terms provides a more accurate 
characterisation of each paper’s focus, as these are systematically categorized through an 
intense indexing process by examiners. We use the MESH term “Anti-Bacterial Agents 
[D27.505.954.122.085]” to search in PubMed, also only within the research area of pharmacy. 
We obtain a list of PubMed IDs (PMID - the unique identifier number used in PubMed) of a 
paper. We then use this PMID to search in Web of Science and to obtain further information 
on these papers, allowing analysis of publications including authors (e.g. co-authorship from 
China or UK).  
Case studies on established and new antibiotics in China are also used to address the second 
question, by looking beyond publications towards commercialisation. Documentary evidence 
and insights from elite interviews will be drawn upon to understand patterns of antibiotic 
innovation in China and the structures and incentives at play. Four case studies (detailed in 
Table 2) are used to illustrate the timeframe and dynamics of development of different 
indigenously-produced antimicrobial compounds, some of which are “new to world”. These 
new drugs are detailed in the Chinese reports or other media, with information checked 
against the website of the Chinese Food and Drug Administration (CFDA) to include drugs 
which were entirely developed by the local companies in China with no foreign investment. 
The case studies provide a systematic way to analyze the drugs’ innovation, history including 
the key contributions of R&D, and other aspects of the innovation process. 
 
4. Recent history of innovation policies relating to antibiotics in China – towards 
mission-oriented innovation policy? 
This section traces the development of science, technology and innovation policies in China 
with the intention of considering the extent to which they can be considered “mission-
oriented” (as per the discussion above) towards antibiotic innovation. The section draws on 
elite interviews and a range of policy documents (outlined in chronological order in Appendix 
1, which also illustrates which government bodies were involved in their design and 
implementation). This allows an assessment of the first element of mission-oriented 
innovation policy – co-ordination across R&D investments. 
4.1 Heritage Elements of Mission-Oriented Innovation Policy Based on National Plans 
In our interviews, policy makers always traced China’s innovation policies concerning AMR 
back to 2006, after the state council initiated the Medium to Long-Term National Plan (MLP) 
for the Development of Science and Technology (2006-2020) (China State Council 2006). A 
highly influential document, the MLP identified 16 National Scientific and Technological Major 
Projects (国家科技重大专项), each of which focused on a relatively broad area of research. 
Antibiotics were included in two such projects, namely those on “New Drugs Development” 
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and on “Prevention and Control of Major Infectious Diseases”, which were launched from 
2008.  
However, the Medium to Long-Term Plan for the Development of Science and Technology 
was not the first national plan for science and technology in China, nor the first national plan 
mentioning innovation in antibiotics. The “Long-term Plan for the Development of Science 
and Technology for 1956–1967” formulated in 1956 (China State Council 1956) set 12 areas 
for major projects, including nuclear weapons, rocket/missile technology and crystallized 
bovine insulin (Wang 2016). Other projects were later added to the plan in response to social 
and political needs, such as the project on satellite technology (which led to the first Chinese 
satellite Dong Fang Hong I in 1974), and another project on the creation of new drugs to cure 
malaria (which resulted in the development of the drug Artemisinin mentioned above - see 
Zhang & Zhang 2019). Interestingly, this 12 year (1956-1967) plan also mentioned the creation 
of new antibiotics and their application in the agriculture, industrial and food sectors.  Its 
inclusion was due primarily to the lack of capability in the Chinese pharmaceutical/ drugs 
industry and the threat of many infectious diseases at that time (China State Council 1956). 
These early innovation policies, which were based on national plans and mobilized resources 
through administrative measures and commands, were the original form of the “whole nation 
system,” in the absence of market-based mechanisms. 
China’s research policies are still framed in the context of national plans, and adapt to the 
new situation every few years. Before the emergence of the National Scientific and 
Technological Major Project for “New Drugs Development” since 2006, the National High-tech 
R&D Program (“863 Program”) which was initiated in 1986 also set biological and medical 
research as one of the major focal areas and supported several projects on innovation of new 
antibiotics (Yixian 2019).  In 1989 the State Pharmaceutical Administration started the 
“National New Drug Fund” (国家新药研究基金) to support new drug discovery at a time 
when imitation was still the main strategy for China’s drug development. It aimed to transform 
the copying strategy into the “creation and copying (模仿创新)” strategy (SDA 1989). In 1993 
the state council established the national leading group for the coordination of new drug 
research and development and this leading group initiated a “1035 project” on new drug 
research and development in China (Chen and Chen 2019). This project set goals for the 9th 
five-year plan: to develop 10 new drugs with patent protection, support the establishment of 
five new drug screening centers, five drug safety evaluation centers, and five drug clinical trial 
and research centers by the end of the 20th century, which represented the desire to establish 
a modern innovation system for drug development (Chen and Chen 2019). In 2001, the 
Ministry of Science and Technology started the National Major Science and Technology Project 
(国家重大科技专项) "Innovative medicine and modernization of traditional Chinese 
medicine" as part of the 10th five-year plan (MOST 2005). These national research projects 
were both responses to international competition and national demand, and underpinned the 
wider national goal to establish a modern innovation system for drug discovery. 
Thereafter, the National Science and Technology Major Projects（国家科技重大专项） 
which started from 2008 can be seen as extensions of the classic mission-oriented S&T major 
research projects such as “atomic and hydrogen bombs”, “man-made satellites”, “manned 
space flight”.  These historical projects illustrate the ability of China’s national political system 
to concentrate resources to realize national targets. From the perspective of the Ministry of 
S&T, the national major projects were seen as the core of China’s development, designed to 
mobilize resources to serve specific national goals such as development of key products, 
breakthrough of key technologies and other engineering projects (MOST 2006). Combining 
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the advantage of the socialist system in concentrating resources with an increasing 
appreciation for the role of the market mechanism, the National Medium-Long Term Plan 
(2006-2021) mentioned above chose 16 specific  areas which a) responded to market demand 
generated by economic and social development and b) represented major bottlenecks in 
further development (MOST 2006). From 2006 to 2018, there were about 150-200 antibiotic  
R&D related research projects supported by the government’s major projects, with a total 
amount of funding of 400 million Yuan RMB (National Health Commission 
2017)(approximately USD 60 million. 
There are some important differences between the recentmajor S&T research projects and 
the major projects in 1960s. The biggest difference relates to changes in the innovation system.   
Researchers were all employed by the government in the 1960s and they had permanent 
positions.  The research teams were organized by the government, which could mobilize 
national resources and researchers to work on critical problems.  The biggest reward for 
researchers was not money but fame and progress within the system (Oldham et al. 1997). 
On the contrary, present innovation systems are marketized and the major S&T research 
projects are competitively funded.  Intellectual property benefits brought by research have 
become a new dominant motivation for researchers, so the coordination and mobilization 
between the state and across different research teams is much more difficult and to some 
extent unrealistic (Li and Su 2014). A competitive application process for funding characterises 
the operation of the Major S&T research project around new drug discovery, although the 
focus and direction of research is decided by the researchers themselves.  This means that the 
outputs of major S&T research projects rely heavily on the individual reputation and 
performance of researchers, rather than the earlier model of a national coordinated approach 
towards targets (Li and Su 2014).  
However, the MLP and present major projects do appear to echo the classic mission-
oriented innovation policy of the Manhattan/ Apollo project forms in other ways. The state 
still tries to play an important role in providing guidance and concentrating resources within 
the national innovation system.  The combination of market-mechanisms and traditional 
elements based on national plans can be said to form what is now known as the “new whole 
nation system” (新举国体制) (National Health Commission 2018).  
 
4.2 The Formation of a Mission around AMR: Domestic and International Influences 
The Chinese government’s growing concern about AMR is the result of both domestic and 
international influences. As a matter of fact, China has been aware of the dangers of AMR and 
has been responding through policy for many years. In 2004-5, the Ministry of Health 
established a monitoring system of antibiotics clinical application and antibiotic resistance, 
“China Antimicrobial Resistance Surveillance System” (CARSS) (National Health Commission 
2017). It started to provide basic information about the use of antibiotics and the status of 
resistance across a network of hospitals. The work of CARSS was strengthened in 2012, 
extending its monitoring range from 149 hospitals in 2011 to 1349 hospitals in 2012. 
In 2009, various health system reforms aimed to achieve rational use of drugs by decoupling 
the income of doctors and their drug prescriptions for patients (He 2019). However, in 2010, 
dangerous levels of antibiotic abuse caused great concern about AMR, leading to the first 
concerted national action for controlling AMR. The Ministry of Health initiated a three-year 
campaign on regulation of antimicrobial drugs in 2011 (Xiao et al 2013; Xiao and Li 2016), 




“The turning point for Chinese governance of AMR should be seen as 2010 (not 2016), as a 
matter of fact. China established the CARSS from 2004, and in 2010 the CARSS revealed that 
the problem of AMR was serious at that time, so the Ministry of Health took many 
administrative measures to regulate the use of antibiotics. (statement of Interviewee F, 
Appendix 2)”  
 
This campaign was purely a domestic response to the problem (Interview records of 
Interviewee F, Appendix 2). In 2012, the Ministry of Health issued the Administrative 
Measures for the Clinical Use of Antibacterial Drugs, which restricted the abuse of antibiotics 
in medical treatment and was also an important output of the three-year campaign (Ministry 
of Health 2012). From 2010, it is clear that AMR entered into the policy agenda for the Ministry 
of Health and became a focus for policy makers. Awareness of the problem of AMR also 
gradually began to permeate wider society. 
International influences also accompanied these domestic actions. In 2011, the WHO 
identified “combatting antimicrobial resistance” as the theme for the World Health Day (Qu, 
Huang, and Lyu 2019). The Ministry of Health and WHO jointly held the world’s first 
conference on rational drug use and the opening ceremony for World Health Day (WHO 2011). 
The representatives from WHO and the Ministry of Health both emphasized the urgency of 
taking action on AMR (WHO 2011). The minister Mao Xiaowei who was responsible for the 
above campaign attended that meeting and introduced the actions needed in this area 
(Interview records of Interviewee F, Appendix 2). However, the international influences were 
not the major driving force for the restriction of usage of antibiotics: 
 
“China took actions to regulate the use of antibiotics at an early stage, this was not due to 
international influence but because of the self-awareness of the problem. (statement of 
Interviewee F, Appendix 2)” 
 
2015 was an important point for Chinese policy concerning AMR. At the 68th World Health 
Assembly, it adopted the Global Action Plan on Antimicrobial Resistance (Qu, Huang, and Lyu 
2019). The Global Action Plan set five strategic objectives including improving awareness, 
strengthening knowledge, reducing infection, optimizing the use of agents and increasing 
investment in new medicines, diagnostics tools, vaccines and other interventions (WHO 2015). 
The Global Action Plan also required each country to make a national action plan to tackle the 
problem (WHO 2015).  
After this, China took two further actions in 2016. One was the establishment of a joint 
working mechanism for the prevention and control of AMR, which consisted of 12 ministries. 
According to an interview with a representative of the National Health Commission, two 
regular meetings are held each year for the joint working mechanism to report on progress 
(Interview records of Interviewee F, Appendix 2).  The National Health Commission, the 
Ministry of Agriculture and Countryside, the Ministry of Science and Technology are the main 
players in the mechanism. The other action was the adoption of the “National Action Plan to 
Contain Antimicrobial Resistance (2016-2020)” by 14 ministries (National Health Commission 
2017). It highlighted the importance of AMR in other ministries beyond the Ministry of Health 
and included actions to restrict the antibiotics use in agriculture, the surveillance of antibiotics 
in the environment, as well as more publicity to improve awareness. Innovation and industrial 
polices about antibiotics from different ministries were also for the first time coordinated 
around tackling AMR (National Health and Family Planning Commission 2016). Therefore, the 
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Action Plan made AMR a clear target of the whole nation and society, and one of the 
important policy issues for most ministries.  
 
4.3 The Convergence of Mission-Oriented Innovation Policy Elements 
The National Action Plan and joint working mechanism provided the opportunity for China 
to coordinate the work of different departments and also the opportunity to integrate the 
elements of mission-oriented innovation policy into one framework. The National Action Plan 
itself did not increase investment, nor add any new antibiotic innovation policy instruments. 
However, considering that antibiotics had only been a part of the previous major S&T research 
project on new drug discovery, the drafting and implementation of the Action Plan formed a 
clearer mission around antibiotic innovation, and made it possible to coordinate public 
investment from different areas. According to a government official from outside the Ministry 
of Health: 
 
“The government released a policy named the National Action Plan to Contain Antimicrobial 
Resistance some years ago. This National Action Plan contains the concrete requirement for 
each Ministry - The Ministry of Science and Technology are making and executing relevant 
policies under the request of this National Action Plan. I think the release of this National 
Action Plan testifies to the high attention from central government on these issues. (statement 
of Interviewee C, Appendix 2)”. 
 
The National Action Plan also had indirect impacts on later innovation polices. From 2016, 
many new national research plans or projects, such as the “Outline of the Healthy China 2030 
Plan” and “Plan and Guidance for Pharmaceuticals development” in 2016, “The 13th five-year 
plan for TCM science and technology innovation”, “The 13th five-year plan for Hygiene and 
Health Science and Technology innovation”, “National Key Technologies R&D Program of 
‘modernization of TCM’ and ‘R&D of Key Food safety technology’ (2017-2021) in 2017, clearly 
included antibiotic innovations.  
The 2018 Status Report on Antimicrobial Administration and Antimicrobial Resistance in 
China clearly stated that research and development on new antibiotics will be enhanced by a 
targeted and merit-based approach under the new whole nation system (National Health 
Commission 2018). On this basis, combined with the co-ordinating actions of the 2016 Action 
Plan and joint working mechanism, we could say that the first pillar of mission-oriented 
innovation policy (co-ordinated R&D policy) has been fulfilled, as a new mission was clearly 
added to the “new whole nation system”. 
With regards to the other pillar of mission-oriented innovation policy, measures to shape 
the market are still to some extent lacking, however at least three measures exist. The first 
regards subsidies from National Basic Medical Insurance scheme towards using new 
antibiotics. The 2018 Status Report (National Health Commission 2018) mentioned that China 
will list new innovative drugs on the National Drug Catalogue for Basic Medical Insurance - a 
useful market-pull incentive for the clinical application of innovation outputs. This policy has 
been implemented for some antibiotics.  For example, Etimicin (approved in 1999) was listed 
in the China National Reimbursement Drug List (NRDL) in 2009 (Fan and Zhao 2019); 
Cefathiamidine (approved in 1994) has been listed in several provinces’ RDLs since 2005 and 
was later added into NRDL (Bioon 2007); Antofloxacin Hydrochloride, an innovative 
fluoroquinolone antibiotic (found in 1993 and approved in 2009), has been listed on several 
provinces’ Reimbursement Drug list since then (Dong 2018). Furthermore, as part of the 
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negotiation process of the NRDL in 2019, many innovative drugs were listed including an 
innovative antibiotic “Nemonoxacin” which had just been approved in 2016 (Zhejiang-
Medicine 2019). 
The second market shaping policy is the accelerated process for sales on the market. The 
China Food and Drug Administration (CFDA) opened a “fast track procedure” for new drugs 
produced by major projects in 2006, and issued detailed policies for registration and review 
in 2015.  New innovative kinds of antibiotics, or those suited for specific serious disease 
contexts, can benefit from priority approvals on the basis of these polices (Interview records 
of Interviewee E, Appendix 2). The third policy is the support provided for the manufacturing 
and marketing of new antibiotics. The Ministry of Industry and Information have funds to 
support the commercialization and industrialization of new drugs after their approval. These 
have not been applied recently, because there are still no antibiotics that have emerged during 
this period (Interview records of Interviewee D, Appendix 2). However, similar support was 
used many years ago to support the manufacturing and marketing of Etimicin, an innovative 
aminoglycoside found in 1980s and approved in 1997 (Fan and Zhao 2019). Specifically, after 
it had been approved in 1997, Etimicin was included in the national “Torch Plan,” which aimed 
at promoting the commercialization and industrialization of high-technology products (Fan 
and Zhao 2019). 
Here, it is important to recognize that - due to their common pool resource nature - 
antibiotics are different from other kinds of products that are usually incentivised by mission 
oriented innovation policy, such as renewable energy technologies, in which their ever-
increasing use is to be welcomed. Rational and therefore limited use of antibiotics is vitally 
important (more important than the innovation of new antibiotics) in the battle against 
antimicrobial resistance.  In China, the situation has improved considerably since 2011 as 
discussed above, however intrinsic contradictions exist between the fast-track approvals/ 
reimbursement subsidy through the NRDL and the regulations for rational use. As discussed 
below, this raises key questions about the ‘market-shaping’ pillar of mission-oriented 
innovation policy in this case, and the even more severe co-ordination challenges that this 
brings to national and international policy processes.   
 
What does this tell us with regard to our first question?  
1. Do China’s policies to support antibiotics innovation have the characteristics of mission 
oriented innovation policy? If so, how was this policy framework established?  
To summarise, the above review of relevant polices has revealed that the AMR or antibiotic 
innovation are gradually becoming a clear topic and focus, especially after the establishment 
of National Action Plan to Contain Antimicrobial Resistance (2016-2020). Elements of both 
pillars of mission-oriented innovation policy can be identified in China. The National Action 
Plan brought together diverse policies that existed beforehand, and made AMR a mission for 
society. Under this framework, the research policies around antibiotics have a clearer 
direction.  The National Action Plan also expands the toolbox beyond co-ordinated R&D to 
include improved surveillance, rational use in different sectors, publicity and awareness 
raising.  From the perspective of market shaping, the addition of innovative antibiotics to the 
National Basic Medical Insurance, the improvement of fast track drug examinations and 
approvals and the support for manufacturing and marketing through downstream policy 
instruments akin to the historic Torch programme, contribute further to the “mission-oriented” 
nature of China’s antibiotics innovation policy.  We next turn to other data sources to deepen 
12 
 
this answer and to begin to address question 2. 
 
5. Influence of Mission-oriented Innovation Policy on China’s Antibiotic Innovation 
System: Empirical evidence 
5.1 The Rising Research Awareness on Antibiotics 
Historically, China’s policies for supporting antibiotic drug research were not strong enough 
to have had direct impacts on the research process. This did not specify detailed targets for 
researchers in the same ways as other areas, such as the antimalarial research task 40 years 
ago. Before the National Action Plan was adopted in 2016, the national major S&T research 
project was just a new fund for drug discovery and an extension of the National New Drug 
Fund from 1989 (SDA 1989) and the “1035 project” from 1993 (Chen and Chen 2019). 
However, the 2016 National Action Plan integrated elements of mission-oriented innovation 
policy and provided a clearer antibiotics mission for the whole society (including the scientific 
community). How can we trace the impact of these changes in terms of antibiotic innovation 
outcomes? 
First we look at the difference that the elements ofmission-oriented innovation policy 
explored above have made to R&D investment.  We already know that a total amount of 400 
million Yuan RMB (approximately USD 60 million) was invested in targeted antibiotic R&D 
through the MLP major projects between 2016-18 (National Health Commission 2017).  
Another possible piece of evidence is the increasing research focus on antibiotics in response-
mode funding.  The National Science Foundation of China (NSFC) is a research fund to support 
free research which reflects the focus/interest of researchers rather than government-
targeted research.  Using the method described in Section 3 above we can see that support 
from NSFC in the area of antibiotics has increased steadily, over the past decade, both in terms 
of the proportion of the investment (Figure 1), the total amount of money and the number of 
projects (Figure 2). From 2010 to 2019, the total investment from NSFC into research 
mentioning “antibiotics” increased from 10.64 million RMB (approximagely USD 1.6 million) 
to 64.82 million RMB (approximately 10 million) and the number of grants also rose from 37 
to 139. The largest increase was seen after 2016. If we consider the money invested in 
antibiotics as a percentage of the total amount each year from NSFC, we find that the 
percentage of investment in 2010 was only 0.11%, rising to 0.22% in 2019 (Figure 1). Again 
from 2010 to 2015, the increase of percentage was no more than 0.05% while the increase 








Figure 2. Number of NSFC grants for “antibiotics” research and aggregate amounts invested (source: 
https://isisn.nsfc.gov.cn/) 
 
These data seem to suggest an increasing level of interest from academics applying to NSFC 
in antibiotics and/or an increase in reviewers’ support for antibiotics-related research.  
Unfortunately, data is not available to allow us to clarify this.  A further hypothesis is that the 
2016 National Action Plan was responsible for the more rapid increase in antibiotics 
research funding directly after that period.  Even given the increases, the overall amount of 
funding dedicated through the Major projects and the NSFC (counted in the hundreds of 
million RMB or tens of millions USD) is small, given the apparent importance afforded to the 
mission in the policies described in Section 4 above.  It is possible that other funding sources 
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data analysed here, it does appear that high levels of mission-oriented, co-ordinated R&D 
funding in this area were not obtained in the pre-Covid 19 era. To provide a comparison, the 
UK committed approximately USD350 million through a single antibiotics research fund – 
the Fleming Fund – in 2016 (UK Government 2016)2. 
 
  
5.2 Increasing Publications on Antibiotics 
 
Figure 3. Number of papers on AMR – Chinese authors (source = CNKI) 
 
Another approach to exploring the effectiveness of the mission-oriented innovation policy 
for antibiotics is through tracing trends in research outputs. From the data collected from 
CNKI, Figure 3 shows the publication of papers on AMR within the area of Pharmacy, it 
shows a steady increase from 1989-2019. However, it is hard to say whether AMR has 
become more important relative to other areas, as China experienced a dramatic increase in 
its overall publications. Therefore, over that period we compare the papers on AMR with the 
total number of papers in the Pharmacy area. Figure 4 shows the result - that from the 
papers on AMR as a percentage of total pharmacy publications, there is no evident increase 
and the percentage is rising and falling around 0.01%. However, Figure 4 also shows that 
papers on AMR that were supported by NSFC seem to increase steadily from 2006 and 
dramatically after 2015.  This approximately mirrors the trend in funding seen above, which 
may be explained by the National Action Plan raising awareness and interest in antibiotics 
research among independent researchers or reviewers in the NSFC.  However, if this rise was 
a consequence of the increasing numbers of new grants awarded to antibiotics research 
from NSFC shown in Figures 1 and 2, we would expect a delay of possibly one or two years 
before resulting publications emerged.  An alternative suggestion is that NSFC-attributed 
submissions of (and/or positive reviews of) antibiotics-related articles in Chinese language 
journals increased around and following the introduction of the Action Plan, with authors 
framing their research contribution more in line with the national “mission”. 
 
2 Care should be taken in this comparison, however, due to the various approaches to quantification adopted in 
each case.  Within NSFC other relevant work may have been funded, which was not picked up by our chosen 


















Figure 5. Number of Chinese language papers on AMR supported by different funding 
sources (source: CNKI) 
  
Figure 5 delineates the growth of papers on AMR supported by China’s major research funds 
- the NSFC and “863 Program”. Source of funding for papers is directly collected from the 
CNKI database according to the acknowledgement statements of the papers. The dramatic 
increase of NSFC supporting papers happened over the most recent ten years, which is 
consistent with the increase in policy focus. The “863 Program” is an important research 
funding project for cutting-edge research, however after its reform in 2015, the Program was 
integrated into the “National Key R&D Plan”. Before the “863 Program” was terminated, the 
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Figure 6. Number of English language papers on “Anti-Bacterial Agents” from authors in 
the UK and China, and their proportion of world publications in the area of pharmacy 
(source: PubMed, WOS) 
A dramatic increase after 2016 is also reflected in data from international journals. Figure 6 
shows the papers on antibiotics from the UK and China published in international journals, 
both in number and as a percentage of world publications in the area of pharmacy.  The UK 
is consistently a strong research force in this area and published more than 200 papers in 
2000 while China only published 43 papers at that time. However, China’s research output in 
this area has been expanding and overtook the UK in 2007. In 2018, China published 1703 
papers, representing 17.38% of the publications in the world, up from 1.52% in 2000. The 
United Kingdom publications consistently represent around 8% of global publications in this 
area. The increases in international publications also demonstrates a positive improvement 
for China in antibiotic research and innovation. 
 
5.3 Antibiotic innovation case studies 
 
In 2019 July 24th, carrimycin was approved by the Chinese FDA after long-term clinical trials.  
The antibiotic is classified as a Class 1 new drug under the 2016 CFDA classification system - 
it comprises new chemical entities with clinical value, and has never been marketed 
anywhere in the world (MOST 2019). Carrimycin was the first new antibiotic in China 
producing using synthetic biology (MOST 2019) and can be used to treat upper respiratory 
tract infection. It was regarded as one of the most important achievements of the national 
major S&T research project. Since its approval by CFDA, the macrolide has been found to 
display antiviral properties in addition to its antibacterial effects, including against Covid-19 
(Yan et al 2021) and received Phase III trials approval from the US FDA for treatment of 
Covid-19 in December 2021.  This is a particularly recent and important example of China’s 
increasing success the application of new techniques to antibiotics innovation.  However, it 
follows a long history of work in this area. 
 
As a matter of fact, the research that led to carrimycin has taken place for more than 30 
years, as illustrated (alongside other drugs) in Table 2.  It started in 1988 and was originally 
supported by “863 Program,” and later the 973 Program and NSFC (MOST 2019). In 2000, 
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from the regulatory department the year after, with phase III clinical trials for upper 
respiratory tract infection completed in 2009. Only in recent years, this project was mainly 
funded by the “new drug discovery major project” (MOST 2019). This work was completed 
by Wang Yiguang, a researcher from the microbial branch of the Chinese Academy 
of Medical Sciences.  The branch was started in 1956 through the first “Long-term Plan for 
the Development of Science and Technology for 1956–1967,” appealing for development of 
antibiotics to protect the nation’s health (Yixian 2019). Before the 1990s the major task of 
this branch was developing antibiotics which had been found in other countries. In recent 
decades, the discovery of new antibiotics has gradually become the main goal, with 
carrimycin providing a key example. 
 
Under the support of the major project for new drug discovery, other Class 1 new antibiotic 
drugs were approved by China FDA. L-ornidazole was approved in 2009, and morinidazole 
was approved in 2014. These two antibiotics were both mainly developed by pharmaceutical 
companies (National Health Commission 2018) and are not included in Table 2. Besides the 
Class 1 new drugs, the new drug discovery major project also supports the development of 
other drugs. Class 3 new drugs refers to drugs which are introduced to China after having 
been marketed in other countries, and are equivalent to the original drugs in quality and 
efficacy.  Up till 2017, at least 15 such drugs had been approved by the China FDA (National 
Health Commission 2018).  By 2016, there were also 8 new antibiotics in clinical trials. It 
seems the national major S&T research project played a critical role. 
 
Antofloxacin hydrochloride is another Class 1 new drug. Research on this antibiotic started in 
1993 and was also supported by the “863 Program” and the NSFC (Dong 2018). This new 
antibiotic was a new kind of fluoroquinolone (Dong 2018) which became the first drug of its 
kind with indigenous intellectual property rights in China.  It has been in production since 
2009 and by 2016 had benefited at least 1 million people.  In 2018, antofloxacin 
hydrochloride was included in the China National Reimbursement Drug List (NRDL), 
providing a market pull incentive.  
 
Research on carrimycin and antofloxacin hydrochloride was mainly completed by research 
institutions, however the success of both has also involved the engagement of enterprises.  
Public funding provided the basic support in the early stages, especially in the period of lab-
experimentation, whilst cooperation with private firms contributed to the preclinical and 
clinical trials, as well as the production and manufacturing of drugs. The National Major S&T 
research project investment in these two new drugs mainly focused on clinical trials, 
illustrating the important role for government funding in near-to-market research in China. 
 
Table 2 below shows a case study history of four major innovative antibiotics in China, with 
two more drugs - etimycin and cephathiamidine - included alongside carrimycin and 
antofloxacin hydrochloride. In all cases, the innovation process was long and received long-
term, continuous support from public funds and/or enterprises. The National Major S&T 
research project of recent years was just one in a series of research funds supporting 
researchers and companies to continue new drug discovery. Some of these case studies also 
reveal investments in production (eg. Torch Plan) and others illustrate how the subsidies 





In summary, the history of these new antibiotics proves that public funding has long been 
important for the creation of new antibiotics, especially at the basic research stage.  It also 
reveals that public funding has been involved alongside follow-up investment from 
entrepreneurs, with some significant successes. The long-term strategy has been expanding 
projects on new antibiotics at the basic research stage to increase the possibility of drug 
development and support the preclinical and clinical trials of new candidate antibiotics, which 
are undertaken through cooperation with entrepreneurs. As the development of new drugs 
always has a long history, we cannot confirm with any certainty whether recent public 
investments in R&D have increased (or will increase) the number or type of new antibiotics 
development in China. As such, we can currently only provide preliminary answers to our 




Table 2 The innovation process of major original innovative antibiotics in recent years. 
Name Etimicin Antofloxacin hydrochloride Cefathiamidine Carrimycin 
Class Aminoglycoside Fluoroquinolone β-lactam Macrolide 
Research 
timeframe 
1980s-1997 1993-2009 1974-1994-2000 1988-2019 
Research 
process 
In 1980s, a series of chemical 
modifications were undertaken 
based on Gentamicin C1a. 
Etimicin was found, which had 
the lowest ear and renal toxicity. 
For further development, this 
project was supported by the 
National New Drug Fund 国家新
药基金。 Supported by the 
National New Drug Fund, many 
other leading institutions and 
researchers were involved in 
research on pharmacodynamics, 
pharmacology, toxicology and 
quality standards, due to the 
poor research ability of the major 
researcher. 
Since 1993, researchers started to 
study fluoroquinolones, and 
designed and synthesized 62 new 
compounds. In 2009, antoxacin 
hydrochloride, which stood out 
from the competition, was 
successfully approved, becoming 
the first new chemical drug of class 
1 with novel chemical structure 
and independent intellectual 
property rights in China. 
In the 1970s, the research 
group set out to study the 
semi-synthesis of 
cephalosporins and small-
scale laboratory processes. In 
1976 the clinical trials started 
with help of Shanghai 
Huashan Hospital. In 1982, 
cefathiamidine was approved 
for production by Shanghai 
Health Bureau. 
In March 1986, the state launched the 
high-tech research and development 
program (“863 Program”), which 
aimed to improve China's 
independent innovation capacity. 
Meanwhile, genetic engineering 
technology was flourishing in 
domestic biology circles, but little 
research was applied to new drugs. 
Researchers seized upon the 
opportunity of a high-tech approach, 
applied for the antibiotic genetic 
engineering project in 1988, and the 
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After Etimicin got support from 
the National New Drug Fund in 
1989, WuXi Shanhe Group 
started to cooperate with Jiangsu 
Institute of Microbiology. They 
worked together on the 
amplification research and 
preparation of clinical samples. 
Etimicin was approved by the 
CFDA in 1997. 
Anhui Huanqiu pharmaceutical 
company acquired the intellectual 
property of antofloxacin 
hydrochloride and its derivatives. 
They cooperated on preclinical 
studies and phase Ⅰ, Ⅱ and Ⅲ 
clinical research, accelerating the 
pace of new drug research and 
development. 
The drug met difficulties in 
production at an early stage. 
At the end of 1980s, 
Baiyunshan company took 
over this drug and started to 
cooperate on the production. 
It took them many years 
experimentation to reach high 
quality production. In 1993, 
the first factory sample was 
produced, and the drug was 
approved in 1994. They then 
took five years to improve the 
quality of large scale 
manufacturing 
In 2000, the preclinical study of 
Carrimycin was completed, the 
clinical trial approval was obtained 
from the regulatory department in 
2001, the phase III clinical trial was 
completed in 2009, and the new drug 
was approved by the technical review 
in 2014. However the final approval 
document was only given in 2019 
due to a change of standards. 
Policy 
support 
National New Drug Fund; Torch 
Plan; 863 Program; NSFC; The State 
Technological Invention Award; 
National Basic Medical Insurance 
The State Technological 
Invention Award; National 
Basic Medical Insurance 
863 Program; 973 program; NSFC; 
National Major S&T research project 
for new drug discovery 
High-tech demonstration project; 
1035 project; 
National Basic Medical Insurance 
 






Pharmaceutical innovation is capital-intensive, long term and high risk. In the absence of commercial 
R&D investment, state support has been important to develop and maintain Chinese drug discovery 
capabilities, which reside mainly in the public sector. The main early focus of Chinese scientists was 
the production of analogues of drugs developed by foreign companies.  
However since 1989, a series of targeted (vertical) policy instruments has been used to support 
investment in drug discovery (in general, not specifically antibiotics), and to support the development 
of innovative capacity with the aim of “catching up”. In 2001, a framework for supporting national 
major S&T research projects was established as a mechanism available across sectors. In recent years, 
especially since 2006, there has been a more explicit emphasis in China on “endogenous innovation” 
(Gu and Lundvall 2006), alternatively termed “indigenous innovation” (Wilsdon & Keeley 2007)(自主
创新).  As a result, the National S&T Major Research Project on new drug discovery has devoted 
further resources to creating new drugs. Some of these National S&T Major Research Projects have 
focused on antibiotics and have the potential to become a core element of the first pillar of a mission 
oriented innovation policy for antibiotics. However, to some extent the National S&T Major Research 
Projects remain focused on “catching up”, rather than more ambitious, mission-oriented investment 
in response to the grand challenge of antimicrobial resistance.  This is particularly reflected in the 
modest levels of investment that are apparent from our analyses. However, there is evidence that 
China’s capabilities in producing novel antibiotics are improving.  
 
From organisational mission to national mission  
The mission of creating new antibiotics initially came not from a national plan but rather from the 
self-appointed mission of individual research institutes. This is most clear from following case studies 
of antibiotic innovation, which have their origins in research institutes, established with modest 
resources, that have had an antibiotic-related mission since the 1950s. These institutes have long-
established research capabilities, which have benefitted from the increase in resources resulting from 
market reforms and a series of national R&D programmes.  
Before these funding initiatives, the institutes developing antibiotics such as Etimicin and 
Cefathiamidine faced extreme resource limitations.  They have also had to adapt to the introduction 
of market reforms and associated competition. On the one hand, these difficulties meant that 
Cefathiamidine’s development took 20 years. However, from the end of the 1980s antibiotic 
developers were able to access support from both public funding programmes and private enterprises, 
accelerating the process. Carrimycin has had a less difficult development process as it benefited at 
the outset from the support of the “863 Program”. Later on it was also supported by NSFC and 
National Major S&T Research Project for new drug discovery. Carrimycin’s production drew upon 
synthetic biological techniques, and hence this was a highly unusual project at a time when most of 
Chinese research was focused on imitating known drugs.  
The above innovations have their origins in the first national research plan for science and technology 
(1956-1967) which focused on organizing researchers directly by establishing institutes and providing 
basic funding. This strategy was widely used in defence and space technologies. During the 1980s 
competitive funding mechanisms for research became more prevalent and the role of central 
22 
 
planning reduced. At the present time most researchers and companies access support under 
competitive modes of funding. The national research plans and 2006 projects for new drug discovery 
involved researchers pursuing, in many different directions, innovation for “creating new drugs”, and 
with no particular emphasis on AMR. While antibiotic drug development is pursued by some 
researchers, it is a relatively small part of overall activity. The 2016 National Action Plan may provide 
the opportunity for a clearer mission focused on new antibiotics, and could also provide an 
opportunity to coordinate the existing elements of mission oriented innovation into a more coherent 
and cohesive form, which – through enhanced investment and appropriate market shaping – could 
bring significant benefits. 
As the NSFC grant data and historical event analysis seems to reflect, the 2016 national action plan to 
contain AMR has drawn more researchers into the field of antibiotic drug discovery as well as 
engaging other ministries beyond the Ministry of Health. The plan may also improve awareness of 
the challenge of AMR in society as a whole. The National Action Plan may lead to an increase in AMR 
related basic research, and may lead to increases in research support from different ministries. A 
growth in basic research here would provide a platform for researchers to obtain further support later 
on from the national major S&T research project in new drug discovery as well as from commercial 
enterprises. The National Action Plan could also provide a policy framework for market-shaping - to 
coordinate the subsidies for new drugs from NRDL, and the subsidies and other preferential policies 
for industrialization processes, such as the fast track approval process for drugs. Although policy 
coordination is far from cohesive at present, the joint working mechanism established in 2016 could 
be used to help strengthen coordination across ministries in the future.  These developments 
illustrate a slow move towards a national mission-oriented innovation policy around antimicrobial 





By analyzing the R&D activities, publications and policies relevant to antibiotics innovation in China, 
this paper reveals how China has been developing its antibiotic R&D and innovation capabilities and 
at the same time evolving towards a configuration with more of the characteristics of mission oriented 
innovation policy. 
The analysis has revealed the emergence of elements of mission oriented innovation policy including: 
(1) the establishment of specialist research institutes, dating back to the 1950s; (2) the broadening 
and deepening of funding through a series of co-ordinated policy instruments such as the national 
major research project based on the 2006 Medium-Long-Term Plan on Science and Technology and 
other research plans & major projects; (3) a series of market-shaping policies including the fast track 
approval of new drugs, reimbursement of treatments for healthcare providers for use of new 
antibiotics listed in the NRDL, and subsidies for the industrialization and commercialization processes. 
While many of the specific policy instruments are conceived more broadly than just antibiotics, they 
include some specific provisions for antibiotics as a priority.  
More focused policies related to AMRhave been emerging since 2008 in China as this became a 
growing domestic problem as well as being increasingly recognized internationally as global challenge. 
In particular, the 2016 National Action Plan to Contain AMR identifies a clear mission to tackle the 
problem of AMR and provides the opportunity to coordinate and integrate a range of policies into a 
coherent mission-oriented innovation policy. Specifically, the National Action Plan provides the 
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chance to reconfigure China’s efforts from the mission of “catching up” towards a “Grand Challenge” 
mission.  
The intrinsic contradictions/ tensions between market creation through the fast-track approvals/ 
NRDL reimbursement processes and the regulations around rational use raise important questions 
that are peculiar to the AMR case.  Mission oriented innovation policy around antibiotics must adopt 
a different approach to that in other fields from the perspective of market shaping, in order to 
incentivize innovation but also limit product use. Rather than a “market entry reward” supported by 
public procurement or subsidies, a sophisticated and finely-tuned approach to antibiotic purchase 
and use is crucially important. This regulation may reduce the market for antibiotics in the short term 
but will also protect their value and market in the long term. One potential innovation policy would 
include the expectation of the limited use of antibiotics but longer-term protection of intellectual 
property to incentivize stewardship of the drug.  Alternatives, currently being piloted in various 
countries, are attempting to de-link the relationship between sales/ revenue for the pharmaceutical 
industry and volume of drug used (Gotham et al 2021). The complex interactions between these 
regulatory approaches and their role in co-ordinating the behavior of different system actors in 
different contexts require further research, both from a theoretical perspective and through policy 
experimentation and learning. 
 
Limitations and further research 
This study has some limitations: Only high-level trend analysis of publications and grants, using just a 
few key terms, has been conducted.  This is partly due to limited data availability for the majority of 
funding sources in China.  For grants, more detailed analysis could be conducted by moving beyond 
overall numbers to explore thematic foci and follow developments in different specific areas, such as 
TCM approaches, and different mechanisms of (and responses to) resistance. The AMR-related 
research supported by different major funding programmes could also be studied in more depth (e.g. 
support for areas such as diagnostics, vaccines and other substitutive therapies besides antibiotics). 
For publications in English, more detailed analysis about the authors and their institutions could be 
undertaken, while combining/ comparing the MESH data we collected with alternative MESH terms 
could also be used to provide a fuller picture. The search for antibiotics-related research in CNKI 
publications in Chinese could try to use antibacterials (“抗菌素”) as well as antibiotics (“抗生素”). 
Further research could reveal experts’ and policy makers’ perceptions of the National Action Plan and 
its observed effectiveness, combined with tracking improvements through other metrics such as 
patents or clinical trials. In particular, it may be important to understand whether and how mission-
oriented innovation policy can overcome some of the specific challenges associated with the 
restricted use of new antibiotics that limit their commercial attractiveness.  Given that the National 
Action Plan arose in response to the 2015 World Health Assembly initiative, the type of approach 
employed in this study could also be applied in other countries to compare the extent to which, and 
modalities through which, mission-oriented innovation policies for antibiotics have been adopted.  
Finally, whilst this study covers the time period up to the arrival of the Covid-19 pandemic, patterns 
of biomedical investment, policies and increasing attention to antimicrobial resistance mean that 
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Appendix 1: Timeline of relevant policies and their associated innovation system functions and actors 
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Note: Functions of innovation systems according to Hekkert et al. (2007) 
l Function 1: entrepreneurial activities 
l Function 2: knowledge development 
l Function 3: knowledge diffusion through networks 
l Function 4: guidance of the search 
l Function 5: market formation 
l Function 6: resources mobilization 
l Function 7: creation of legitimacy/counteract resistance to change
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